Nov 2018

Autism Spectrum Disorder (ASD)

Market Insights, Epidemiology and Market

Forecast-2027
 DelveInsight | Page |1

Key Insights
The Report contains:

Overview of pathophysiology, Pipeline analysis across different

various diagnostic approaches Research Pipeline stages of development (Phase III),
and treatment algorithms, Analysis different emerging trends and
including detailed chapters Valuation comparative analysis of pipeline
for marketed products and products with detailed clinical
emerging therapies profiles, key cross - competition,
launch date along with product
development activities
Epidemiology Market
Historical as well as forecasted Forecast Analysis
epidemiology in 7MM- covering
United States, EU5 (Germany,
Spain, Italy, France and United Detailed historical & forecasted
Market size by
Kingdom) and Japan from 2016- market covering United States,
therapies EU5 and Japan countries from
2027
2016-2027

Detailed Market size by therapies, covering United States, EU5

(Germany, Spain, Italy, France and United Kingdom) and Japan
from 2016-2027

Help Develop Strategies,

Insightful Reviews on
Assess Trends Shaping &
Market
Driving the Market
 DelveInsight | Page |2

Report Introduction
DelveInsight’s “Autism Spectrum
Disorder (ASD) - Market Insights,
Epidemiology & Market Forecast-2027”
Report provides an overview of the
disease and market size of Autism
Spectrum Disorder for the seven major
The report provides the understanding of the markets i.e., the United States, EU5
epidemiology and changing market dynamics (France, Germany, Italy, Spain, UK) and
Japan.
of the Autism Spectrum Disorder (ASD) in the The Report covers the overview,
7 major pharmaceutical markets for the treatment practice & Autism Spectrum
Disorder forecasted epidemiology
period 2016-2027 from 2018 to 2027, segmented by
seven major markets.

✓ The report covers descriptive overview of the Autism

Key Strengths
Spectrum Disorder, explaining its causes, signs and
❖ 10 Year Forecast
symptoms, diagnosis and the currently available therapies
❖ 7MM Coverage
✓ The report provides an insight into the epidemiology of the
❖ Epidemiology Segmentation
disease and its treatment in the 7 MM, covering the United
❖ Key Cross Competition
States, EU5 (Germany, Spain, France, Italy, UK) & Japan
❖ Market Size by therapies
✓ The report is a comprehensive account of both the current ❖ Drug Uptake
and emerging therapies, assessing the impact of new ❖ Treatment Modalities
therapies on the current treatment landscape ❖ Market Size by Countries
✓ The report also reviews the detailed global historical and
forecasted Autism Spectrum Disorder market including the Key Assessments

drug outreach in 7 MM ❖ Pipeline Product Profiles

✓ The report helps in developing business strategies by ❖ Key Products and Key Players
❖ Market Drivers and Barriers
understanding trends shaping and driving the global Autism
❖ Company Collaborations
Spectrum Disorder market
❖ Unmet Needs
 DelveInsight | Page |3

Epidemiology Insights

ASD refers to a group of neurodevelopmental conditions defined by impairment in three areas: social interaction,
communication or use of verbal and non-verbal language, and a stereotyped, restricted or repetitive pattern of
behavior, interests and activities. In 2013, the American Psychiatric Association merged four distinct autism
diagnoses into one umbrella diagnosis of autism spectrum disorder (ASD). They included autistic disorder,
childhood disintegrative disorder (CDD), pervasive developmental disorder-not otherwise specified (PDD-NOS)
and Asperger syndrome.

Symptoms of ASD start to appear during the first three years of life. The exact cause of autism spectrum disorder
(ASD) is currently unknown, however it’s a complex condition that may occur as a result of genetic predisposition,
environmental or unknown factors.

ASD occurs in all racial, ethnic, and socioeconomic groups, but is about 4 times more common among boys than
among girls.

Autism Spectrum Disorder Epidemiology

• As per DelveInsight estimates, the total prevalent cases of Autism Spectrum Disorder in 7 major markets
was found to be 6,545,050 in 2016

• Among all the countries, United States accounts for the highest number of prevalent cases of ASD, with
around 3,734,939 cases in 2016

• Among the European countries, UK had the highest prevalent population of Autism Spectrum Disorder with
655,612 cases, followed by Italy which had prevalent population of 357,235 in 2016. On the other hand,
Germany had the lowest prevalent population of 90,333 cases in 2016

• As per the DSM diagnostic subtype criteria of Autism Spectrum, in 2016, there were highest cases of Autistic
disorder with 1,777,831 cases followed by Pervasive Development Disorder with 1,718,072 cases in the
United States
 DelveInsight | Page |4

Epidemiology Segmentation-7MM

Diagnosed Prevalent Cases of Autism Spectrum

Disorder in 7MM
1

Gender Specific Diagnosed Prevalent Cases of Autism

Spectrum Disorder in 7MM 2
2

Subtype Specific Diagnosed Prevalent Cases of Autism Spectrum

Disorder in 7MM 3
[Autistic, PDD-NOS, Asperger and CDD]

%PATIENTS AUTISM SPECTRUM

DISORDER
DelveInsight’s assessment based on US EU5 JP
the recent studies suggests that
overall 57% of the Autism Spectrum
Disorder prevalent cases belongs to
US and 26% of the cases belongs to
57%
EU5 in 7 major markets in 2016
 DelveInsight | Page |5

Graphical Representation of Autism Spectrum Disorder Epidemiology

Diagnosed Prevalent Cases of Autism Spectrum Disorder in 7MM

Diagnosed Prevalent cases of Autism Spectrum Disorder in 7MM

Popuation in numbers (n)

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027

US Germany France Italy Spain UK Japan

Diagnosed Prevalent Cases of Autism Spectrum Disorder in the United States

Diagnosed Prevalent cases of ASD

Population in number (n)

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027

Children Adult
 DelveInsight | Page |6

Gender Specific Diagnosed Prevalent Cases of Autism Spectrum Disorder in the United States

Gender-specific cases of ASD

Population in number (n)

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027

Male: 0-17 yrs Male: 18 & above Female: 0-17 yrs Female: 18 & above

Subtype Specific Diagnosed Prevalent Cases of Autism Spectrum Disorder in the United States

Subtype specific diagnosed prevalent cases

Population in numbers (n)

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Year
Autistic Disorder Pervasive Development Disoder- not otherwise specified
Asperger Disorder Childhood Disintegrative Disorder
 DelveInsight | Page |7

Market Insights

OUTLOOK OF AUTISM SPECTRUM DISORDER MARKET

Key Findings

The therapeutic market for Autism Spectrum Disorder in seven major markets was found to be USD 2510.2
million in 2016 as per DelveInsight assessments, for the study period (2016-2027).

US Scenario [2016] US Scenario [2027]

2016 2027
US EU5 JP US EU5 JP

54% 55%

Among EU5 countries, United Kingdom had the highest market size with USD 255.21 million, while Germany
had the lowest market size of ASD with USD 35.16 million in 2016.

Today, most medicines prescribed to ease autism’s disabling symptoms are used “off label”. These off-label
medicines are generally prescribed to relieve signs and symptoms associated with ASD and are not
definitive cure for ASD. The drugs commonly prescribed to ASD patients include antipsychotics
antidepressants, selective-serotonin reuptake inhibitors, stimulants, anticonvulsants, antihypertensives, CNS
depressants and others. Many alternative and complementary therapies can also be used, however there
is no research to show that they are effective. Some of these therapies include behavior and
communication therapies, education therapies, family therapies, creative therapies (art therapy or music
therapy), sensory-based therapies, special diets, chelation therapy and acupuncture.
 DelveInsight | Page |8

Risperidone (Johnson and Johnson) and Aripiprazole (Otsuka Pharmaceuticals) are the only two
antipsychotics that are FDA-approved for the treatment of irritability in ASD. However, these also have
significant drawbacks and limitations. Not all people respond to these therapies, symptoms often return
when the drug is discontinued, and they doesn’t improve many of the core behaviors associated with
autism.

Market Size of Autism
Spectrum Disorder in the
7MM was found to be USD
2510.2 million in 2016
The market size is expected
to increase at a CAGR of
XX% during the study
period
Despite remarkable advances in the
knowledge of autism made in the past
decade, the treatment of core
symptoms remains a major challenge
in ASD.

Owing to the launch of upcoming Launch of therapies such as CM-AT

therapies, the market size shall (Luminenz-AT) will definitely fuel the
increase during forecast period growth of Autism Spectrum Disorder
(2018-2027) market in the upcoming years

Also, the diagnosis and management of ASD, however is quite a challenge. No pharmacological treatment
currently exists to help improve the challenges that individuals may experience with social skills, repetitive
behaviors, restrictive interests and communication. These core symptoms of ASD may be persistent and
difficult to overcome.

To counter the current unmet needs of the market and to provide better treatment options for ASD, various
research studies have focused on developing novel treatments for ASD treatment. Thus, various
experimental studies are undergoing to find promising therapies for the ASD treatment.

Overall, increase in the awareness for the condition, shifts in the criteria for diagnosing autism and the
launch of upcoming therapies will significantly shift the ASD market during the forecast period (2018-2027).
 DelveInsight | Page |9

7 Major Market Size of Autism Spectrum Disorder

Market size of ASD in 7MM

Sales in USD, Million

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027

United States Germany France Italy Spain United Kingdom Japan

Market Size of Autism Spectrum Disorder in the United States

Market size of ASD in the US

Revenue in USD, Million

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Year
 D e l v e I n s i g h t | P a g e | 10
Drugs Uptake
Market Size by Therapies

Currently, there is no cure for ASD and most medicines are prescribed to ease autism’s disabling symptoms
and are used “off label”. Only two drugs, Riperidone and Apipripazole are FDA approved, however, these
are associated with certain side effects, leaving behind many opportunities for ASD therapeutic market.

Many players are such as Roche, Neurochlore/Servier, Nobelpharma, Johnson and Johnson, Yamo
Pharmaceuticals, Curemark etc. are involved in developing therapies for the treatment of ASD. Therapies
such as Balovaptan (Roche), Bumetanide (Neurochlore/ Servier), L1-79 (Yamo Pharmaceuticals), CM-AT
(Curemark) etc. are under-development for the treatment of ASD.

Balovaptan is a vasopressin receptor antagonist (VRA) for individuals with autism. The drug is under Phase
III stage of development by Roche. Recently, in January 2018, Balovaptan was granted Breakthrough
Therapy Designation by US FDA. The drug is under development for both children and adults with ASD and
is expected to get launched in the market by 2021. The drug is estimated to hold the highest market share
during the forecast period.

CM-AT is under development by Curemark and is in Phase III stage for the treatment of Autism in children.
The drug candidate has received Fast Track Designation for Autism and the company has also begun rolling
NDA submission of CM-AT for the treatment of Autism.

L1-79 is a novel therapy currently in Phase II stage of development by Yamo Pharmaceuticals for the
treatment of the core symptoms of Autism Spectrum Disorder in both children and adults. It has also
received Fast Track Designation by FDA. Previous experience with open-label administration of L1-79 in
patients with autism demonstrated that L1-79 is a well-tolerated.

Bumetanide is under development by Neurochlore/ Servier and is under Phase III stage of development.
The drug is under development for children. Results have shown that Bumetanide constitutes a successful
strategy to treat ASD with several advantages over the 2 FDA approved drugs (Risperdal and Apiriprazole)
endowed with side effects. The drug is expected to hold decent market share during the forecast period.
 D e l v e I n s i g h t | P a g e | 11

Market Size of Autism Spectrum Disorder by Therapies in the United States

Market size of ASD by therapy

Revenue in USD, Million

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027

Antipsychotics Stimulants (Dopamine reuptake inhibitor)

Antiepileptic and mood stabilizer Antihypertensive(adrenergic alpha-2 receptor agonists)
Antidepressants CNS depressants
Others Multiclass Polypharmacy
Balovaptan Bumetanide
L1-79 CM-AT
 D e l v e I n s i g h t | P a g e | 12

Table of Content to View

1. Key Insights 1
2. Autism Spectrum Disorder Market Overview at a Glance 3
2.1. Market Share (%) Distribution of ASD in 2016 3
2.2. Market Share (%) Distribution of ASD in 2027 3
3. Disease Overview: Autism Spectrum Disorder 10
3.1. Introduction 10
3.2. Types of ASD 11
3.3. Etiology of Autism Spectrum Disorder 14
3.4. Pathophysiology of Autism Spectrum Disorder 15
3.5. Signs and Symptoms 25
3.6. Diagnosis 28
3.7. Diagnostic Guidelines 35
3.7.1.Diagnostic Criteria 35
3.7.2.American Academy of Neurology and the Child Neurology Society 41
3.7.3.The National Institute for Health and Care Excellence (NICE) 43
3.8. Diagnostic Algorithm 47
4. Epidemiology and Patient Population 49
4.1. Key Findings 49
4.2. 7MM Total Diagnosed Prevalent Cases of Autism Spectrum Disorder 50
5. Country Wise-Epidemiology of Autism Spectrum Disorder 51
5.1. United States 51
5.1.1.Assumptions and Rationale 51
5.1.2.Diagnosed Prevalent Cases of ASD in the United States 53
5.1.3.Gender Specific Diagnosed Prevalent cases of ASD in the United States 54
5.1.4.Subtype-Specific Diagnosed Prevalent Cases of ASD in the United States 55
5.2. EU5 56
5.3. Germany 56
5.3.1.Assumptions and Rationale 56
5.3.2.Diagnosed Prevalent Cases of ASD in Children in Germany 57
5.3.3.Gender Specific Diagnosed Prevalent Cases of ASD in Germany 58
5.3.4.Subtype-Specific Diagnosed Prevalent Cases of ASD in Germany 59
5.4. France 60
5.4.1.Assumptions and Rationale 60
5.4.2.Diagnosed Prevalent Cases of ASD in France 61
5.4.3.Gender Specific Diagnosed Prevalent Cases of ASD in France 62
5.4.4.Subtype-Specific Diagnosed Prevalent Cases of ASD in France 63
5.5. Italy 64
5.5.1.Assumptions and Rationale 64
 D e l v e I n s i g h t | P a g e | 13

5.5.2.Diagnosed Prevalent Cases of ASD in Italy 65

5.5.3.Gender Specific Diagnosed Prevalent Cases of ASD in Italy 66
5.5.4.Subtype-Specific Diagnosed Prevalent Cases of ASD in Italy 67
5.6. Spain 68
5.6.1.Assumptions and Rationale 68
5.6.2.Diagnosed Prevalent Cases of ASD in Spain 69
5.6.3.Gender Specific Diagnosed Prevalent Cases of ASD in Spain 70
5.6.4.Subtype-Specific Diagnosed Prevalent Cases of ASD in Spain 71
5.7. United Kingdom 72
5.7.1.Assumptions and Rationale 72
5.7.2.Diagnosed Prevalent Cases of ASD in the United Kingdom 73
5.7.3.Gender Specific Diagnosed Prevalent Cases of ASD in the United Kingdom 74
5.7.4.Subtype-Specific Diagnosed Prevalent Cases of ASD in the United Kingdom 75
5.8. Japan 76
5.8.1.Assumptions and Rationale 76
5.8.2.Diagnosed Prevalent Cases of ASD in Japan 77
5.8.3.Gender Specific Diagnosed Prevalent Cases of ASD in Japan 78
5.8.4.Subtype-Specific Diagnosed Prevalent Cases of ASD in Japan 79
6. Treatment Practices 80
7. Treatment Guidelines and Recommendations 91
7.1. American Academy of Child & Adolescent Psychiatry 91
7.2. National Institute for Health and Care Excellence (NICE) 91
8. Treatment Algorithm 93
9. Unmet Needs 94
10. Marketed Drugs 96
10.1. Risperdal: Johnson and Johnson 96
10.1.1. Drug Description 96
10.1.2. Regulatory Milestones 96
10.1.3. Advantages & Disadvantages 97
10.1.4. Clinical Development 97
10.1.5. Safety and Efficacy 98
10.1.6. Product Profile 99
10.2. Abilify: Otsuka Pharmaceutical 100
10.2.1. Drug Description 100
10.2.2. Regulatory Milestones 100
10.2.3. Advantages & Disadvantages 102
10.2.4. Clinical Development 102
10.2.5. Safety and Efficacy 103
10.2.6. Product Profile 103
10.3. Slenyto: Neurim Pharmaceuticals 105
 D e l v e I n s i g h t | P a g e | 14

10.3.1. Drug Description 105

10.3.2. Regulatory Milestones 105
10.3.3. Advantages & Disadvantages 105
10.3.4. Clinical Development 106
10.3.5. Safety and Efficacy 106
10.3.6. Product Profile 107
11. Emerging Therapies 108
11.1. Key cross competition- Emerging Therapies 108
11.2. Balovaptan: Roche 109
11.2.1. Product Description 109
11.2.2. Other Developmental Activities 109
11.2.3. Clinical Development 109
11.2.4. Safety and Efficacy 110
11.2.5. Product Profile 111
11.3. Bumetanide: Neurochlore/Servier 112
11.3.1. Product Description 112
11.3.2. Other Developmental Activities 112
11.3.3. Clinical Development 112
11.3.4. Safety and Efficacy 114
11.3.5. Product Profile 114
11.4. CM-AT: Curemark 115
11.4.1. Product Description 115
11.4.2. Other Developmental Activities 115
11.4.3. Clinical Development 116
11.4.4. Safety and Efficacy 117
11.4.5. Product Profile 117
11.5. L1-79: Yamo Pharmaceuticals 119
11.5.1. Product Description 119
11.5.2. Other Developmental Activities 119
11.5.3. Clinical Development 119
11.5.4. Safety and Efficacy 120
11.5.5. Product Profile 120
12. Autism Spectrum Disorder: 7 Major Market Analysis 121
12.1. Key Findings 121
12.2. Market Size of Autism Spectrum Disorder in 7MM 122
13. Market Outlook by Country 123
14. The United States: Market Outlook 123
14.1. United States Market Size 127
14.1.1. Total Market size of Autism Spectrum Disorder 127
14.1.2. Autism Spectrum Disorder Market by Therapies 128
 D e l v e I n s i g h t | P a g e | 15

15. EU-5 Countries: Market Outlook 130

15.1. Germany 132
15.1.1. Total Market size of Autism Spectrum Disorder 132
15.1.2. Autism Spectrum Disorder Market by Therapies 133
15.2. France 135
15.2.1. Total Market size of Autism Spectrum Disorder 135
15.2.2. Autism Spectrum Disorder Market by Therapies 136
15.3. Italy 138
15.3.1. Total Market size of Autism Spectrum Disorder 138
15.3.2. Autism Spectrum Disorder Market by Therapies 139
15.4. Spain 141
15.4.1. Total Market size of Autism Spectrum Disorder 141
15.4.2. Autism Spectrum Disorder Market by Therapies 142
15.5. United Kingdom 144
15.5.1. Total Market size of Autism Spectrum Disorder 144
15.5.2. Autism Spectrum Disorder Market by Therapies 145
16. Japan: Market Outlook 147
16.1. Total Market size of Autism Spectrum Disorder 148
16.2. Autism Spectrum Disorder Market by Therapies 149
17. Market Drivers 151
18. Market Barriers 152
19. Appendix 154
19.1. Report Methodology 154
20. DelveInsight Capabilities 156
21. Disclaimer 157
22. About DelveInsight 157
 D e l v e I n s i g h t | P a g e | 16

List of Tables
Table 1: Single gene disorders with the high rate of autism 18
Table 2: Changes in the diagnostic criteria for the PDDs in the DSM-5 (adapted from Ozonoff) 32
Table 3: Differential diagnosis of language disorders 34
Table 4: Severity Levels of Autism Spectrum Disorder 36
Table 5: Severity Levels of Autism Spectrum Disorder 37
Table 6: Organisation and delivery of care 43
Table 7: NICE Guideline, Core Autism Features 43
Table 8: 7MM Total Diagnosed Prevalent Cases of Autism Spectrum Disorder (2016-2027) 50
Table 9: Diagnosed Prevalent Cases of ASD in the United States (2016-2027) 53
Table 10: Gender Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027) 54
Table 11: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United States (2016-
2027) 55
Table 12: Diagnosed Prevalent Cases of Autism Spectrum Disorder in Germany (2016-2027) 57
Table 13: Gender Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027) 58
Table 14: Subtype-Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027) 59
Table 15: Diagnosed Prevalent Cases of Autism Spectrum Disorder in France (2016-2027) 61
Table 16: Gender Specific Diagnosed Prevalent Cases of ASD in France (2016-2027) 62
Table 17: Subtype-Specific Diagnosed Prevalent Cases of ASD in France (2016-2027) 63
Table 18: Diagnosed Prevalent Cases of ASD in Italy (2016-2027) 65
Table 19: Gender Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027) 66
Table 20: Subtype-Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027) 67
Table 21: Diagnosed Prevalent Cases of ASD in Spain (2016-2027) 69
Table 22: Gender Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027) 70
Table 23: Subtype-Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027) 71
Table 24: Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027) 73
Table 25: Gender Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-
2027) 74
Table 26: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-
2027) 75
Table 27: Diagnosed Prevalent Cases of ASD in Japan (2016-2027) 77
Table 28: Gender Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027) 78
Table 29: Subtype-Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027) 79
Table 30: Essential characteristics of effective interventions for children with autism
spectrum disorder 83
Table 31: Consensus recommendations of pharmacological treatment of co-occurring
conditions and symptoms in children and adults with ASD 88
Table 32: Recommendations 91
 D e l v e I n s i g h t | P a g e | 17

Table 33: Antipsychotic medication for behaviour that challenges 91

Table 34: Sleep problems 91
Table 35: What is needed to inform the families in care? 92
Table 36: Key points for the general paediatrician 92
Table 37: Risperdal, Clinical Trial Description, 2018 98
Table 38: Abilify, Clinical Trial Description, 2018 103
Table 39: Slenyto, Clinical Trial Description, 2018 106
Table 40: Key cross competition- Emerging Therapies 108
Table 41: Balovaptan, Clinical Trial Description, 2018 110
Table 42: Bumetanide, Clinical Trial Description, 2018 113
Table 43: CM-AT, Clinical Trial Description, 2018 116
Table 44: L1-79, Clinical Trial Description, 2018 119
Table 45: 7 Major Market Size of Autism Spectrum Disorder in USD Million (2016-2027) 122
Table 46: United States Market Size of Autism Spectrum Disorder in USD Millions (2016-
2027) 127
Table 47: United States Market Size of ASD by Therapies in USD Million (2016-2027) 128
Table 48: Germany Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 132
Table 49: Germany Market Size of ASD by Therapies in USD Million (2016-2027) 133
Table 50: France Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 135
Table 51: France Market Size of ASD by Therapies in USD Million (2016-2027) 136
Table 52: Italy Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 138
Table 53: Italy Market Size of ASD by Therapies in USD Million (2016-2027) 139
Table 54: Spain Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 141
Table 55: Spain Market Size of ASD by Therapies in USD Million (2016-2027) 142
Table 56: United Kingdom Market Size of Autism Spectrum Disorder in USD Millions (2016-
2027) 144
Table 57: UK Market Size of ASD by Therapies in USD Million (2016-2027) 145
Table 58: Japan Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 148
Table 59:Japan Market Size of ASD by Therapies in USD Million (2016-2027) 149
 D e l v e I n s i g h t | P a g e | 18

List of Figures
Figure 1: Types of Autism Spectrum Disorder 11
Figure 2: Converging Mechanisms of Autism Spectrum Disorder 21
Figure 3: Types of Autism Spectrum Disorder 47
Figure 4: 7MM Total Diagnosed Prevalent Cases of Autism Spectrum Disorder (2016-2027) 50
Figure 5: Diagnosed Prevalent Cases of ASD in the United States (2016-2027) 53
Figure 6: Gender Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027) 54
Figure 7: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United States (2016-2027) 55
Figure 8: Diagnosed Prevalent Cases of Autism Spectrum Disorder in Germany (2016-2027) 57
Figure 9: Gender Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027) 58
Figure 10: Subtype-Specific Diagnosed Prevalent Cases of ASD in Germany (2016-2027) 59
Figure 11: Diagnosed Prevalent Cases of Autism Spectrum Disorder in France (2016-2027) 61
Figure 12: Gender Specific Diagnosed Prevalent Cases of ASD in France (2016-2027) 62
Figure 13: Subtype-Specific Diagnosed Prevalent Cases of ASD in France (2016-2027) 63
Figure 14: Diagnosed Prevalent Cases of ASD in Italy (2016-2027) 65
Figure 15: Gender Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027) 66
Figure 16: Subtype-Specific Diagnosed Prevalent Cases of ASD in Italy (2016-2027) 67
Figure 17: Diagnosed Prevalent Cases of ASD in Spain (2016-2027) 69
Figure 18: Gender Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027) 70
Figure 19: Subtype-Specific Diagnosed Prevalent Cases of ASD in Spain (2016-2027) 71
Figure 20: Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-2027) 73
Figure 21: Gender Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-
2027) 74
Figure 22: Subtype-Specific Diagnosed Prevalent Cases of ASD in the United Kingdom (2016-
2027) 75
Figure 23: Diagnosed Prevalent Cases of ASD in Japan (2016-2027) 77
Figure 24: Gender Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027) 78
Figure 25: Subtype-Specific Diagnosed Prevalent Cases of ASD in Japan (2016-2027) 79
Figure 26: Unmet Needs for Autism Spectrum Disorder 94
Figure 27: 7 Major Market Size of Autism Spectrum Disorder in USD Million (2016-2027) 122
Figure 28: United States Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 127
Figure 29: United States Market Size of ASD by Therapies in USD Million (2016-2027) 128
Figure 30: Germany Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 132
Figure 31: Germany Market Size of ASD by Therapies in USD Million (2016-2027) 133
Figure 32: France Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 135
Figure 33: France Market Size of ASD by Therapies in USD Million (2016-2027) 136
Figure 34: Italy Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 138
Figure 35: Italy Market Size of ASD by Therapies in USD Million (2016-2027) 139
 D e l v e I n s i g h t | P a g e | 19

Figure 36: Spain Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 141
Figure 37: Spain Market Size of ASD by Therapies in USD Million (2016-2027) 142
Figure 38: United Kingdom Market Size of Autism Spectrum Disorder in USD Millions (2016-
2027) 144
Figure 39: UK Market Size of ASD by Therapies in USD Million (2016-2027) 145
Figure 40: Japan Market Size of Autism Spectrum Disorder in USD Millions (2016-2027) 148
Figure 41: Japan Market Size of ASD by Therapies in USD Million (2016-2027) 149
Figure 42: Market Drivers 151
Figure 43:Market Barriers 152
 D e l v e I n s i g h t | P a g e | 20

Appendix
Report Methodology
DelveInsight is a premier source for pharmaceutical and biotechnology sector analysis, delivering
exclusive, trusted commercial insight into industry performance through its proprietary platform.
DelveInsight’s reports are continuously updated and revised. The following research methodology
is followed for all databases and reports.

Coverage
The objective of updating DelveInsight coverage is to ensure that it represents the most up to date
vision of the industry possible. The DelveInsight is a fully-integrated solution for comprehensive
intelligence on various pharmaceutical products, both in-market and in pipeline, across the globe.

Sources Used
Secondary Research
The secondary research on internal and external sources is being carried out to source qualitative
and quantitative information relating to each market. The secondary research sources that are
typically referred to include, but are not limited to:
• Company websites, annual reports, financial reports, broker reports, investor
presentations and SEC Filings Industry trade journals and other literature
• Internal and external proprietary databases
• National government documents, statistical databases and market reports
• News articles, press releases and web-casts specific to the companies operating in the
market

Primary Research
DelveInsight conducts primary research by interacting with the healthcare professionals, doctors,
industry’s experts and industry participants and commentators in order to validate its data and
analysis. The discussion provides first-hand information on the market size, market trends, growth
trends, competitive landscape, future outlook, for example.
• It helps in validating and strengthening the secondary research findings
• It further develops the Analysis Team’s expertise and market understanding
• An interactive one-stop, fully integrated business intelligence (BI) platform, catering the
need of the global pharmaceuticals market, across all the value chains
• The comprehensive integration allows for the seamless comparison of the market
dynamics, helps strategic planning and decision making to stay competitive in the global
pharmaceuticals industry
• We help our clients to find answers relevant to business decision-making, including
potential market opportunities, competitor assessments and business environmental
 D e l v e I n s i g h t | P a g e | 21

dynamics enhances companies’ to plan development, trials or research process based on

their competitor focus

Forecast Methodology
DelveInsight Reports are prepared considering different epidemiology and market factors, keeping
past and current trends in focus. Our forecasting models are prepared based on
the Hybrid approach, where we use both top to bottom and bottom to top approaches and
analyze different factors and parameters to forecast the numbers.

We develop a deep understanding by doing systemic literature research for Epidemiological data
around different geographies. We prepare the forecast model based on different data sources,
considering past and current trends from different factors such as Improvements in survival and
disease therapy, Unmet need, Risk of disease by gender and age group, population size, diagnose
trends, treatment factors and others.

Our Market Forecast model consider factors such as unmet medical need, drug competitor factor,
patient compliance, product price, Marketed drugs- calibration based on actual sales and their
impact in different geographies, emerging drugs and their impact, Novel Agents Analysis based on
their results, therapeutic potential, regulatory success, launch dates, etc., market challenges,
drivers and barriers, and other factors.

Our major sources are company annual reports, scientific literature, epidemiology studies
conducted by different agencies, Pub-Med Articles, country specific government released
population sources and others. To keep up with current market trends, we try to take doctors,
KOLs and industry experts’ opinion through secondary as well as primary research to come with
the actual market size.

Expert Panel Validation

DelveInsight uses a panel of experts to cross verify research and forecast methodologies, and drive
its analytical content. The DelveInsight expert panel comprises of marketing managers, product
specialists, international sales managers from pharmaceutical companies; academics from
research universities and consultants from professional services companies.
 D e l v e I n s i g h t | P a g e | 22

DelveInsight Capabilities
DelveInsight Consulting Services collaborate with Biotech & Pharmaceutical companies, Venture
Capitalist, R&D units & API manufacturers to help them in critical business decisions, building
commercial excellence and growing businesses in an increasingly competitive and challenging
environment.
Competitive Intelligence

Conference/Congress
Intelligence

Market/BD
Assessment Studies

R&D
Analytics

Forecasting
Primary CI

DelveInsight delivers strategic CI Inputs to clients for monitoring competition and staying ahead via
our expertise in gathering industry intelligence, leading to better decision making.
1
Our in-depth insights helps market research and business development teams of global bio-Pharma
companies in understanding the market, identifying and targeting the untapped opportunities. 2
DelveInsight’s forecasting through epidemiology-based and unit-based methodologies help create
flexible and robust models to accommodate key inputs for effective market forecasting. 3
DelveInsight’s CI team has supported many global clients by delivering CI projects with high-quality
insights, helping improve their business processes, combining primary and secondary research
methods and validating information to provide un-biased insights. 4
DelveInsight’s subject matter experts help deliver high-quality insights, supporting clients in key
decisions like prioritizing indications, analyzing clinical trials, & analyzing the patents & publications. 5
Our in-house conference/congress intelligence experts gather information from various websites
of congresses and analyze the data to map the KOLs attending the congresses, to effectively plan 6
congresses etc. and provide our un-biased analysis.
 D e l v e I n s i g h t | P a g e | 23

Report Price
Autism Spectrum Disorder (ASD)

Market Insights, Epidemiology and Market Forecast-2027

USD 6250
Single User License

USD 9500
2-3 Users License

USD 12500
Site License

USD 18750
Corporate License
 D e l v e I n s i g h t | P a g e | 24

Disclaimer
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval
system or transmitted in any form by any means, electronic,
mechanical, photocopying, recording or otherwise, without the prior
permission of the publisher, DelveInsight.

The facts of this report were believed to be correct at the time of

publication but cannot be guaranteed. Please note that the findings,
conclusions and recommendations that DelveInsight delivers will be
based on information gathered in good faith from both primary and
secondary sources, whose accuracy we were not always in a position
to guarantee.

As such DelveInsight can accept no liability whatever for actions taken based on any information
that may subsequently prove to be incorrect.

About DelveInsight
DelveInsight is a Business Consultant company and serve as a Knowledge partner across the value
chain of Pharmaceutical Industry. With the use of proprietary databases and analytical models,
DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all
therapy areas to the Pharma and biotech sector, helping clients to quantify market events and
evaluate their impact on the valuation of products, portfolios and companies. Additional
information is available at www.delveinsight.com.

For further information or queries, please contact the Sales Team, DelveInsight
at salessupport@delveinsight.com or info@delveinsight.com